Bromodeoxyuridine: A comparison of its photosensitizing and radiosensitizing properties

Department of Neurological Surgery, School of Medicine, University of California, San Francisco.
Journal of Neurosurgery (Impact Factor: 3.74). 10/1988; 69(3):410-5. DOI: 10.3171/jns.1988.69.3.0410
Source: PubMed


The photo- and radiosensitizing properties of bromodeoxyuridine (BUdR) were assessed in vitro using the 9L rat brain tumor cell line. Pretreatment of 9L cells with 10 microM BUdR for 24 hours followed by irradiation with ultraviolet (UV) light resulted in a dose-enhancement ratio of 3.8:1 compared with UV radiation alone. X-radiation of BUdR-pretreated cells produced a dose-enhancement ratio of 1.7:1. Alkaline elution analysis of deoxyribonucleic acid (DNA) from cells treated with BUdR and UV irradiation showed the presence of DNA single-strand breaks and DNA-protein cross-links. Analysis of DNA from cells treated with BUdR and then x-irradiated showed no increase in DNA single-strand breaks compared with cells treated with x-radiation alone; no DNA-protein cross-links could be detected. The possible clinical relevance of these findings is discussed.

7 Reads

  • Interface Science and Technology 01/2008; 16. DOI:10.1016/S1573-4285(08)00203-2
  • [Show abstract] [Hide abstract]
    ABSTRACT: A variety of clinical reports have described the application of the bromodeoxyuridine labeling index as an adjunct to conventional pathological examination of CNS tumors. This index has proven useful in predicting the clinical outcome associated with many such tumors. Furthermore, because of its efficacy as a radiosensitizing agent, bromodeoxyuridine (and the closely related iododeoxyuridine) has been used in combination with radiation therapy for malignant glial neoplasms, with some encouraging results. Although most studies suggest that bromodeoxyuridine is safe, there is evidence that this compound does have potential side-effects, including the observation that it is a mutagen and carcinogen in some experimental systems. A number of new alternative approaches for predicting the clinical outcome of CNS tumors has been developed based on an increased understanding of their molecular biology. However, until such approaches are better characterized, the clinical application of bromodeoxyuridine will continue to play an important role in predicting the clinical behavior of many CNS tumors.
    Journal of Neuro-Oncology 02/1994; 20(1):81-95. DOI:10.1007/BF01057964 · 3.07 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In the past two decades, the technology of laser cytometry and use of the halogenated thymidine (HP) analogues bromodeoxyuridine and iododeoxyuridine as proliferation labels, have allowed us to quantify the rate of cell turnover in tissues and tumours, in clinical samples as in laboratory models. The principal studies have used injection of bromo- or iododeoxyuridine to measure cell production rates in vivo. Flow cytometry (FCM) has been used to estimate the S phase labelling index (LI) and the S phase duration (Ts) and calculate the cell production rate, represented by the potential doubling time (Tpot). This has allowed calculation of time-dependent indices of proliferation from single biopsies of HP pulse labelled human tissues and tumours. In the first part of this two-part review, we describe the technique and its limitations as a biological assay. The second part summarizes the knowledge gained about cell production rates and the relevance that this information may have to future investigative, prognostic and treatment strategies.
    European Journal of Surgical Oncology 05/2000; 26(3):227-38. DOI:10.1053/ejso.1999.0781 · 3.01 Impact Factor
Show more